Globalepolicy.org is a free to access global medical news service for the consumer, professional and researcher.
Our adviser: Drugs Infromation online
Background: A treatment algorithm and screening examination have been developed to guide patient management and prospectively determine potential for highly active individuals to succeed with nonoperative care after anterior cruciate ligament rupture.
Objective: To prospectively characterize and classify the entire population of highly active individuals over a 10-year period and provide final outcomes for individuals who elected nonoperative care.
Methods: Inclusion criteria included presentation within 7 months of the index injury and an International Knee Documentation Committee level I or II activity level before injury. Concomitant injury, unresolved impairments, and a screening examination were used as criteria to guide management and classify individuals as noncopers (poor potential) or potential copers (good potential) for nonoperative care.
Results: A total of 832 highly active patients with subacute anterior cruciate ligament tears were seen over the 10-year period; 315 had concomitant injuries, 87 had unresolved impairments, and 85 did not participate in the classification algorithm. The remaining 345 patients (216 men, 129 women) participated in the screening examination a mean of 6 weeks after the index injury. There were 199 subjects classified as noncopers and 146 as potential copers. Sixty-three of 88 potential copers successfully returned to preinjury activities without surgery, with 25 of these patients not undergoing anterior cruciate ligament reconstruction at the time of follow-up.
Conclusion: The classification algorithm is an effective tool for prospectively identifying individuals early after anterior cruciate ligament injury who want to pursue nonoperative care or must delay surgical intervention and have good potential to do so.
NAVIGATION
|
9
Feb |
Medtronic Issues Statement On District Court Ruling Regarding CoreValveCategory: Litigation / Medical Malpractice | Leave a Comment |
Medtronic, Inc. (NYSE: MDT) announced that the U.S. District Court of Delaware issued its ruling on post-trial motions filed by the parties in Edwards Lifesciences v. CoreValve, Inc. In its ruling, the Court denied Edwards Lifesciences’ request for a permanent injunction to prohibit Medtronic from manufacturing its CoreValve® System in the U.S…
|
14
Jan |
Judge Orders Guidant To Pay $296 Million Fine For Withholding Information About Faulty Heart DevicesCategory: Litigation / Medical Malpractice | Leave a Comment |
This Boston Scientific Corp. subsidiary faces this fine as well as three years of probation as part of a case that began in 2005. The Associated Press/Los Angeles Times: Judge In Guidant Heart Device Case Says Company Must Pay Over $296M, Serve 3 Years’ ProbationBoston Scientific Corp…
|
2
Jan |
Korean Court System Finds Taeyeon Kyphoplasty Device Infringes A Medtronic Kyphoplasty PatentCategory: Litigation / Medical Malpractice | Leave a Comment |
Medtronic, Inc. has announced that the High Court in Seoul, Korea has found that the balloon kyphoplasty device made by Taeyeon Medical Co., Ltd. infringes a valid Medtronic patent and has ordered destruction of Taeyeon’s stock of the infringing device and related manufacturing equipment…
|
11
Oct |
Texas Woman Brings Suit Against DePuy Orthopedics And Johnson & Johnson For Defective Artificial Metal-on-Metal Hip ImplantCategory: Litigation / Medical Malpractice | Leave a Comment |
Wendy R. Fleishman, a partner in the national plaintiffs’ law firm Lieff Cabraser Heimann & Bernstein, LLP, announces that Estella M. Wahl and Terry Wahl have filed a personal injury lawsuit against DePuy Orthopedics, Inc., and its parent company, Johnson & Johnson, Inc…
|
29
Apr |
AstraZeneca Settles Drug Marketing Lawsuit, Plea Deal Rejected For Possibly Defective Heart Device MakerCategory: Litigation / Medical Malpractice | Leave a Comment |
The New York Times: AstraZeneca has settled a case and agreed to pay $520 million after federal investigations into its marketing practices for a schizophrenia drug, Seroquel. The announcement came Tuesday from Attorney General Eric Holder…
|
22
Apr |
Legal Case Asks Who To Blame For Medical Device FailureCategory: Litigation / Medical Malpractice | Leave a Comment |
The New York Times: A legal case now pending asks a question increasingly faced by the medical world — “who should be held accountable when a company sells a flawed product that can injure or kill patients? Is it the company or the people who run it?” Five years ago, two cardiologists discovered that a company had been knowingly selling faulty heart defibrillators that…
|
15
Feb |
Subject Sentenced To 51 Months For Sale Of Unapproved Medical DevicesCategory: Litigation / Medical Malpractice | Leave a Comment |
United States Attorney Karen P. Hewitt announced that James Folsom was sentenced in federal court in San Diego to serve 51 months in custody and a $250,000 fine following his conviction on twenty-six felony counts relating to the sale of unapproved medical devices and the commission of offenses while on pretrial release. The Honorable John A…
|
15
Mar |
Injected Medication Errors “a Serious Safety Problem” In Intensive Care UnitsCategory: Litigation / Medical Malpractice | Leave a Comment |
Errors in the administration of injected (parenteral) medication occur with alarming frequency, and are a serious safety problem in intensive care units, concludes a large study published on bmj.com today. A previous study found that medication errors were frequent at the administration stage, so Dr Andreas Valentin and colleagues set out to examine this further on a multinational level.
|
15
Mar |
Injected Medication Errors “a Serious Safety Problem” In Intensive Care UnitsCategory: Litigation / Medical Malpractice | Leave a Comment |
Errors in the administration of injected (parenteral) medication occur with alarming frequency, and are a serious safety problem in intensive care units, concludes a large study published on bmj.com today. A previous study found that medication errors were frequent at the administration stage, so Dr Andreas Valentin and colleagues set out to examine this further on a multinational level.
|
13
Mar |
Suit Against Medtronic Is DismissedCategory: Litigation / Medical Malpractice | Leave a Comment |
Medtronic, Inc. (NYSE:MDT) today announced that a securities class action lawsuit against the company was dismissed by U.S. District Judge Richard Kyle of Minnesota. The complaint, which was filed initially by Stanley Kurzweil on behalf of all shareholders and amended on April 18, 2008 after consolidation with other similar shareholder suits, involved the company’s October 2007 withdrawal of its Sprint Fidelis defibrillator leads.